(Q41104921)

26 September 2017

1 reference

title

Inhaled glucocorticoids: new developments relevant to updating of the asthma management guidelines (English)

1 reference

26 September 2017

1 reference

Barnes PJ

1

1 reference

26 September 2017

1 August 1996

1 reference

26 September 2017

1 reference

26 September 2017

90

1 reference

26 September 2017

7

1 reference

26 September 2017

379-384

1 reference

Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma

26 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Binding kinetics of fluticasone propionate to the human glucocorticoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

The human pharmacology of fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Efficacy and safety of inhaled corticosteroids in asthma. Report of a workshop held in Eze, France, October 1992.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

New perspectives on inhaled drug delivery and systemic bioactivity

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Inhaled glucocorticoids for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Evaluation of fluticasone propionate (500 micrograms day-1) administered either as dry powder via a Diskhaler inhaler or pressurized inhaler and compared with beclomethasone dipropionate (1000 micrograms day-1) administered by pressurized inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Comparison of the efficacy and safety of inhaled fluticasone propionate 200 micrograms/day with inhaled beclomethasone dipropionate 400 micrograms/day in mild and moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

A comparison of fluticasone propionate 200 micrograms/day with beclomethasone dipropionate 400 micrograms/day in adult asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. The Fluticasone Propionate Asthma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Treatment of severe steroid dependent preschool asthma with nebulised budesonide suspension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

High dose nebulized steroid in the treatment of chronic steroid-dependent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Large volume spacer devices and the influence of high dose beclomethasone dipropionate on hypothalamo-pituitary-adrenal axis function

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Effect of a volumatic spacer and mouth rinsing on systemic absorption of inhaled corticosteroids from a metered dose inhaler and dry powder inhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Importance of the inhalation device on the effect of budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Clinical efficacy of budesonide Turbuhaler compared with that of beclomethasone dipropionate pMDI with volumatic spacer. A 2-year randomized study in 102 asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Airway mucosal inflammation even in patients with newly diagnosed asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

Cessation of long-term treatment with inhaled corticosteroid (budesonide) in children with asthma results in deterioration. The Dutch CNSLD Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2896%2990108-0

7 January 2021

10.1016/S0954-6111(96)90108-0

Identifiers

DOI

1 reference

26 September 2017

1 reference

PubMed ID

8796227